Share this:
Print Friendly, PDF & Email

AZ Shows Off osimertinib setting the groundwork for move into 1L EGFRm+ NSCLC

AZ´s symposium presentations focused on promoting the value of 3rd Gen TKIs and liquid biopsies. AZ took the opportunity to emphasize that osimertinib is the only 3rd Gen TKI in the market highlighting the discontinuation of rociletinib and BI´s disengagement with olmutinib. Osimertinib´s positive data in 1L and 2L with/without T790 mutation was shown; the AURA pooled data from n=397 patients shows ORR=66% with 80mg QD dose. AZ then set the stage for its entry into 1L showing a pooled analysis from AURA 1L cohorts – essentially a rehash of the ELCC 2016 data showing a PFS=19.3 months across n=60 1L patients, with 160 mg QD dose.

Related Post

Sakshi Saini
Sakshi Saini
Sakshi has a passion for healthcare and innovation in medical techs (Rx and devices). Her ability lies in providing an "outside-in" perspective to colleagues involved in the design, development and commercialization of medical innovation. She comes with a wide range of experience in the oncology space pertaining to both solid tumors and blood malignancies (Lung, Colorectal, Melanoma,AML and MDS).She works with RAS clients to provide activities related to market research and competitive intelligence. She is also a member of European Society of Clinical Oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *